Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Viking Therapeutics is attracting takeover interest following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals. Investors are closely monitoring Viking's obesity drug pipeline, specifically VK2735 and the new Phase 1 trial for VK3019.
Why it matters
The obesity drug market is seeing massive consolidation, making mid-cap biotech firms with promising clinical assets prime targets for major pharmaceutical acquisitions.
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal Bailey Pemberton Wed, July 8, 2026 at 5:12 AM EDT 4 min read VKTX +1.11% VRTX -2.24% CRNX +0.10% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
The article reports on market speculation and financial news without taking a political or ideological stance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in